Galimedix is focusing on Phase 2 studies of GAL-101 eye drops for neuroprotective and symptomatic therapy to slow progression and to improve visual function in glaucoma and dry AMD patients, both being neurodegenerative diseases of the retina in the eye. In parallel, an oral version of GAL-101 is being advanced towards Phase 1 clinical trials aiming for use in ophthalmology and Alzheimer's disease. A next generation molecule GAL-201 may also be directed to central nervous system (CNS) diseases such as Alzheimer's disease. Galimedix’ lead program is its Phase 2 GAL-101 eye drops, to demonstrate proof of concept using established study endpoints in glaucoma and dry AMD, while addressing those large markets of high unmet medical need. Clinical proof of concept for GAL-101 in the eye will also support use of oral GAL-101 in Alzheimer's disease and other indications.